» Articles » PMID: 36059459

SCD2-mediated Cooperative Activation of IRF3-IRF9 Regulatory Circuit Controls Type I Interferon Transcriptome in CD4 T Cells

Overview
Journal Front Immunol
Date 2022 Sep 5
PMID 36059459
Authors
Affiliations
Soon will be listed here.
Abstract

Type I interferons (type I-IFN) are critical for the host defense to viral infection, and at the same time, the dysregulation of type I-IFN responses leads to autoinflammation or autoimmunity. Recently, we reported that the decrease in monounsaturated fatty acid caused by the genetic deletion of is essential for the activation of type I-IFN signaling in CD4 Th1 cells. Although interferon regulatory factor (IRF) is a family of homologous proteins that control the transcription of type I-IFN and interferon stimulated genes (ISGs), the member of the IRF family that is responsible for the type I-IFN responses induced by targeting of SCD2 remains unclear. Here, we report that the deletion of triggered IRF3 activation for type I-IFN production, resulting in the nuclear translocation of IRF9 to induce ISG transcriptome in Th1 cells. These data led us to hypothesize that IRF9 plays an essential role in the transcriptional regulation of ISGs in -deleted (sg) Th1 cells. By employing ChIP-seq analyses, we found a substantial percentage of the IRF9 target genes were shared by sg and IFNβ-treated Th1 cells. Importantly, our detailed analyses identify a unique feature of IRF9 binding in sg Th1 cells that were not observed in IFNβ-treated Th1 cells. In addition, our combined analyses of transcriptome and IRF9 ChIP-seq revealed that the autoimmunity related genes, which increase in patient with SLE, were selectively increased in sg Th1 cells. Thus, our findings provide novel mechanistic insights into the process of fatty acid metabolism that is essential for the type I-IFN response and the activation of the IRF family in CD4 T cells.

Citing Articles

The role of cisplatin in modulating the tumor immune microenvironment and its combination therapy strategies: a new approach to enhance anti-tumor efficacy.

Li G, Che X, Wang S, Liu D, Xie D, Jiang B Ann Med. 2025; 57(1):2447403.

PMID: 39757995 PMC: 11705547. DOI: 10.1080/07853890.2024.2447403.

References
1.
Dalskov L, Narita R, Andersen L, Jensen N, Assil S, Kristensen K . Characterization of distinct molecular interactions responsible for IRF3 and IRF7 phosphorylation and subsequent dimerization. Nucleic Acids Res. 2020; 48(20):11421-11433. PMC: 7672473. DOI: 10.1093/nar/gkaa873. View

2.
Kessler D, Veals S, Fu X, Levy D . Interferon-alpha regulates nuclear translocation and DNA-binding affinity of ISGF3, a multimeric transcriptional activator. Genes Dev. 1990; 4(10):1753-65. DOI: 10.1101/gad.4.10.1753. View

3.
Kanno T, Nakajima T, Yokoyama S, Asou H, Sasamoto S, Kamii Y . SCD2-mediated monounsaturated fatty acid metabolism regulates cGAS-STING-dependent type I IFN responses in CD4 T cells. Commun Biol. 2021; 4(1):820. PMC: 8242023. DOI: 10.1038/s42003-021-02310-y. View

4.
Gough D, Messina N, Clarke C, Johnstone R, Levy D . Constitutive type I interferon modulates homeostatic balance through tonic signaling. Immunity. 2012; 36(2):166-74. PMC: 3294371. DOI: 10.1016/j.immuni.2012.01.011. View

5.
Cheng Z, Dai T, He X, Zhang Z, Xie F, Wang S . The interactions between cGAS-STING pathway and pathogens. Signal Transduct Target Ther. 2020; 5(1):91. PMC: 7293265. DOI: 10.1038/s41392-020-0198-7. View